Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

How China Inc. Aims To Take Over Cell Therapy Dominance

Speed, Partnerships Shine for Small CAR-T Players

Executive Summary

Just three years after its founding, Chinese cell therapy developer IASO Bio already has two assets in clinical development and the Nanjing firm has recently attracted $60m in financing. In an exclusive interview, its R&D head told Scrip that speed and partnerships are propelling Chinese developers on a trajectory to quickly catch up with the west in the emerging cell-therapy arena.

You may also be interested in...



Asia Deal Watch: Cancer Collaborations, Licensings Lead Activity In Asia

Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.

Video Panel: How China Inc. Sells Latest Therapies In An Untapped Market

During the “Road to Commercialization” panel session during EBD/Informa Connect's recent annual ChinaBio partnering event, senior executives from top Chinese biotechs along with a leading contract manufacturing organization and venture fund shared views on biologics commercialization in China. Partnerships to accelerate the process, as well as the future commercial direction of novel biologics in their fastest-growing market worldwide, were also discussed.

Cellular Biomedicine To Go Private In Consortium Buyout

Deal Snapshot: The China/US CAR-T firm will be bought out by its management team and institutional investors in a deal structured as a merger into a new company.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM011995

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel